Breath Biopsy Testing Market Report 2026

The breath biopsy testing market size has grown strongly in recent years. It will grow from $3.43 billion in 2025 to $3.69 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing demand for non-invasive diagnostics, expansion of clinical research on breath biomarkers, advancements in sensor and spectroscopy technologies, growth of diagnostic laboratory services, rising patient preference for painless testing.

The breath biopsy testing market size is expected to see strong growth in the next few years. It will grow to $4.9 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to increasing adoption of breath-based diagnostics in routine screening, rising investments in ai-enabled diagnostic platforms, expansion of personalized medicine applications, growing use of portable diagnostic devices, increasing regulatory support for non-invasive testing. Major trends in the forecast period include increasing adoption of non-invasive diagnostic techniques, rising use of voc-based disease detection, growing integration of AI-driven breath analysis, expansion of portable breath sampling devices, enhanced focus on early disease screening.

The rising prevalence of respiratory diseases is expected to drive the growth of the breath biopsy testing market in the coming years. Respiratory diseases are medical conditions that affect the lungs and airways, impairing a person’s ability to breathe efficiently. Their prevalence is increasing due to factors such as environmental pollution, higher smoking rates, and the growing occurrence of chronic conditions like asthma and chronic obstructive pulmonary disease (COPD). Breath biopsy testing provides a non-invasive, rapid, and potentially more accurate method for detecting biomarkers linked to these conditions, improving early diagnosis and management. For example, in May 2025, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that COPD was the fifth leading cause of death in the United States in 2023, accounting for 141,733 deaths. During the same year, the age-adjusted prevalence of diagnosed COPD among adults reached 3.8%. Consequently, the increasing prevalence of respiratory diseases is expected to fuel the growth of the breath biopsy testing market.

Key companies in the breath biopsy testing market are developing innovative products, such as breath analyzers, for detecting asthma. Breath analyzers are diagnostic devices that measure specific compounds in a person’s breath to identify medical conditions or assess health status. For instance, in May 2023, GenWorks, an India-based healthcare solutions provider, launched the FenomPro breath analyzer. The FenomPro features rapid FeNO testing, delivering results in just 28 seconds. Designed for clinical settings, it provides accurate assessments for diagnosing, screening, and monitoring asthma. The device includes a rechargeable battery for portability, a user-friendly interface, and efficiently determines whether patients require treatment or inhaler prescriptions.

In November 2023, Syantra Inc., a Canada-based liquid biopsy platform and innovation company, partnered with Limmi to advance the AI-powered RNA-based early cancer detection liquid biopsy program. This collaboration provides a scalable AI-driven liquid biopsy platform that generates novel insights from clinical data, enhancing Syantra’s ability to detect multiple cancers at early stages. Limmi is a US-based technology company.

Major companies operating in the breath biopsy testing market are Drägerwerk AG & Co. KGaA, Intoximeters Inc., Owlstone Medical Ltd., SKC Inc, Lifeloc Technologies Inc., Alcolizer Pty Ltd., Breathomix, Aerocrine AB, Bedfont Scientific Ltd., AK GlobalTech Corp., Alveo Technologies Inc., Andatech Pty Ltd., BACtrack, Biosensia Ltd., Ionicon, Ketonix AB, Lion Laboratories Limited, Menssana Research Inc., Microplex Inc., Quest Products Inc., Rapid Biosensor Systems Ltd., RoboScientific Ltd., Spirosure.

North America was the largest region in the breath biopsy testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breath biopsy testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the breath biopsy testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the breath biopsy testing market by increasing costs of imported sensors, spectrometry components, electronic analyzers, and data processing hardware. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported analytical instruments, while Asia-Pacific faces pricing pressure on device manufacturing and exports. These tariffs are raising equipment acquisition costs and slowing adoption in smaller clinics. However, they are also encouraging local sensor manufacturing, regional device assembly, and innovation in cost-efficient breath diagnostic technologies.

The breath biopsy testing market research report is one of a series of new reports that provides breath biopsy testing market statistics, including breath biopsy testing industry global market size, regional shares, competitors with a breath biopsy testing market share, detailed breath biopsy testing market segments, market trends and opportunities, and any further data you may need to thrive in the breath biopsy testing industry. This breath biopsy testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Breath biopsy testing is a non-invasive diagnostic approach that examines the chemical compounds in a person’s breath to detect and diagnose diseases. This testing relies on the principle that certain diseases, metabolic conditions, and physiological states produce unique chemical markers, known as volatile organic compounds (VOCs), which can be identified in exhaled breath.

The main types of breath biopsy testing include volatile organic compound analyzers, breath biopsy kits, breath samplers, and others. Volatile organic compound (VOC) analyzers are devices designed to detect and measure the concentration of VOCs in the air. These analyzers utilize various technologies, such as fuel cell technology, semiconductor sensors, infrared (IR) spectroscopy, and others, and are employed in hospitals, clinics, diagnostic laboratories, and similar healthcare settings.

The breath biopsy testing market consists of revenues earned by entities by providing services such as metabolic disorder screening, gastrointestinal health assessment, predictive screening and non-invasive testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The breath biopsy testing market also includes sales of breath collection devices, diagnostic software, portable breath testers and wearable breath sensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.